Effect of Bacillus subtilis C-3102 on loose stools in healthy volunteers.

M Hatanaka, K Yamamoto, N Suzuki, S Iio, T Takara, H Morita, T Takimoto, T Nakamura

Journal: Beneficial microbes 2018;9(3):357-365

PMID: 29482338

Full Text on Sheridan PubFactory View on PubMed

Plain Language Summary

The cause of IBS has yet to be established, however the role of the gut microbiota in modulating symptoms is the subject of significant recent research. This randomised, double-blind, placebo controlled trial of 88 healthy subjects with chronic diarrhoea, aimed to assess the impact of ingestion of probiotic strain Bacillus subtilis C-3102 over an 8 week period on patient symptoms. Approximately 8.5 billion spores of Bacillus subtilis C-3102 were administered daily to the treatment group, once a day, immediately after breakfast. The results, after 8 weeks of ingestion, showed: an improved Bristol Stool Chart score; a reduction in stool frequency; significantly decreased abdominal sounds; and significantly altered relative abundance of Lachnospira, Actinomyces and SMB53. Intake of 4 weeks or more were required to achieve these results. Even though this was a small study, nutrition and lifestyle practitioners looking to support the digestive health of IBS patients may wish to consider adding this probiotic strain to their recommendations on the grounds of improved symptoms of diarrhoea.

Abstract

Ingestion of Bacillus subtilis C-3102 spores (C-3102) has relieved the symptoms of diarrhoea in piglets and changed the composition of gut microbiota in humans. Recently, it was suggested that the composition of the human gut microbiota affects stool consistency. In this study, a double-blind, randomised, placebo-controlled trial was conducted to assess the preventive effects of chronic diarrhoea in healthy volunteers with loose stools by ingestion of C-3102. The results showed that oral doses of C-3102 tablets significantly decreased the Bristol Stool Scale score and stool frequency, and also significantly improved abdominal sounds. With regard to gut microbiota, the relative abundance of Lachnospira, Actinomyces and SMB53 were significantly changed. This study shows that C-3102 could be effective for treating loose stools (Trial registration: UMIN000022583, http://tinyurl.com/ya4refqn ).

Address: 1 Department of Microbiological Flora Techinology, Core Technology Laboratories, Asahi group holdings Ltd., 5-11-10 Fuchinobe, Chuo-ku, Sagamihara-shi 252-0206, Kanagawa, Japan.; 2 R&D Department, Orthomedico Inc., 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo 112-0002, Japan.; 3 Medical Corporation Seishinkai, Takara Clinic, 9F Tasei Building, 2-3-2 Higashi-gotanda, Shinagawa-ku, Tokyo 141-0022, Japan.

DOI: 10.3920/BM2017.0103

Physical Environment

Infectious Agents

Clinical Imbalances

Gastro-intestinal

Laboratory Testing

Stool

Nutrition Evidence Keywords

IBS Probiotics Diarrhoea Irritablebowelsyndrome Bacillussubtilis

Bioactive Substances

Bacillussubtilis Lachnospira Actinomyces SMB53

Link outs

Free resources

Other Literature Sources:

Subscription / membership required

Full Text Sources:

https://brill.com/doi/10.3920/BM2017.0103

MeSH Terms: Administration, Oral, Antidiarrheals, Bacillus subtilis, Double-Blind Method, Gastrointestinal Microbiome, Healthy Volunteers, Humans, Placebos, Probiotics, Tablets